However, pharmacological inhibition of Atgl, using the inhibitor Atglistatin, does not appear to cause the severe cardiac steatosis or cardiomyopathy observed in genetic models of ATGL disruption (Schweiger et al., 2017). Here, PNPLA2 is linked to cardiomyopathy.